Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab after CAR-T for relapsed or refractory large B-cell lymphoma
jRCTs011260001Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and large-cell lymphoma, sponsored by AbbVie Inc. Primary endpoint: 1-year progression-free survival rate. Started Sep 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphoma
Beyond the preview
Go deeper on jRCTs011260001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011260001.